Skip to main content
Centessa Pharmaceuticals plc logo

Centessa Pharmaceuticals plc — Investor Relations & Filings

Ticker · CNTA ISIN · US1523091007 LEI · 213800GIDAARDSKOI827 US Manufacturing
Open in API
Filings indexed 548 across all filing types
Latest filing 2022-02-24 Regulatory Filings
Country GB United Kingdom
Listing US CNTA

About Centessa Pharmaceuticals plc

https://www.centessa.com/

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that utilizes a Research & Development innovation engine to discover and develop transformational medicines for patients. The company employs a data-driven approach to advance its portfolio of innovative assets. A key program in its pipeline is the development of potential best-in-class, orally administered orexin receptor 2 (OX2R) agonists for the treatment of sleep-wake disorders. Centessa's broader therapeutic focus often includes rare diseases and other areas with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce major events or corporate changes. The content describes a milestone event triggering payment of contingent value rights related to a clinical trial dosing, and a press release issued by the company. There are no financial statements or detailed financial data presented, only a description of the event and a reference to a press release. The document is about an unregistered sale of equity securities and a Regulation FD disclosure, which are typical contents of a current report (8-K). This does not fit the definitions of Annual Report, Earnings Release, or other detailed financial reports. It is a regulatory announcement of a corporate event. Therefore, the best fitting category is Regulatory Filings (RNS). The document length is under 5,000 characters, and it includes a press release as an exhibit, which supports it being a regulatory filing rather than a full report or presentation.
2022-02-24 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 16, 2022, reporting the resignation of a board member, Dr. Robert M. Califf, from the Board of Directors due to his new appointment as FDA Commissioner. The key section is Item 5.02, which relates to changes in directors or officers. There is no financial data or report attached; the document is an announcement of a management change. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3605 characters, which is consistent with a brief announcement rather than a full report.
2022-02-16 English
SC 13G
Major Shareholding Notification
2022-02-14 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a Note Purchase Agreement, including waivers of defaults, changes to financial obligations, and extensions of dates related to financing arrangements. There are no financial statements or detailed financial performance data included, only a description of a financing amendment. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is 6684 characters, sufficient to provide substantive detail on the financing amendment. Therefore, the correct classification is CAP with high confidence.
2022-02-12 English
SC 13G
Major Shareholding Notification
2022-02-08 English
FORM 4 SUBMISSION
Director's Dealing
2022-02-04 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.